Taurochenodeoxycholic acid is an experimental drug that is normally produced in the liver. Its physiologic function is to emulsify lipids such as cholesterol in the bile. As a medication, taurochenodeoxycholic acid reduces cholesterol formation in the liver, and is likely used as a choleretic to increase the volume of bile secretion from the liver and as a cholagogue to increase bile discharge into the duodenum. It is also being investigated for its role in inflammation and cancer therapy.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Lepirudin | The risk or severity of bleeding and bruising can be increased when Lepirudin is combined with Taurochenodeoxycholic acid. |
| Bivalirudin | The risk or severity of bleeding and bruising can be increased when Bivalirudin is combined with Taurochenodeoxycholic acid. |
| Alteplase | The risk or severity of bleeding and bruising can be increased when Alteplase is combined with Taurochenodeoxycholic acid. |
| Urokinase | The risk or severity of bleeding and bruising can be increased when Urokinase is combined with Taurochenodeoxycholic acid. |
| Reteplase | The risk or severity of bleeding and bruising can be increased when Reteplase is combined with Taurochenodeoxycholic acid. |
| Anistreplase | The risk or severity of bleeding and bruising can be increased when Anistreplase is combined with Taurochenodeoxycholic acid. |
| Tenecteplase | The risk or severity of bleeding and bruising can be increased when Tenecteplase is combined with Taurochenodeoxycholic acid. |
| Drotrecogin alfa | The risk or severity of bleeding and bruising can be increased when Drotrecogin alfa is combined with Taurochenodeoxycholic acid. |
| Streptokinase | The risk or severity of bleeding and bruising can be increased when Streptokinase is combined with Taurochenodeoxycholic acid. |
| Dicoumarol | The risk or severity of bleeding and bruising can be increased when Dicoumarol is combined with Taurochenodeoxycholic acid. |
| Argatroban | The risk or severity of bleeding and bruising can be increased when Argatroban is combined with Taurochenodeoxycholic acid. |
| Ardeparin | The risk or severity of bleeding and bruising can be increased when Ardeparin is combined with Taurochenodeoxycholic acid. |
| Phenindione | The risk or severity of bleeding and bruising can be increased when Phenindione is combined with Taurochenodeoxycholic acid. |
| Fondaparinux | The risk or severity of bleeding and bruising can be increased when Fondaparinux is combined with Taurochenodeoxycholic acid. |
| Warfarin | The risk or severity of bleeding and bruising can be increased when Warfarin is combined with Taurochenodeoxycholic acid. |
| Pentosan polysulfate | The risk or severity of bleeding and bruising can be increased when Pentosan polysulfate is combined with Taurochenodeoxycholic acid. |
| Phenprocoumon | The risk or severity of bleeding and bruising can be increased when Phenprocoumon is combined with Taurochenodeoxycholic acid. |
| Heparin | The risk or severity of bleeding and bruising can be increased when Heparin is combined with Taurochenodeoxycholic acid. |
| Enoxaparin | The risk or severity of bleeding and bruising can be increased when Enoxaparin is combined with Taurochenodeoxycholic acid. |
| Acenocoumarol | The risk or severity of bleeding and bruising can be increased when Acenocoumarol is combined with Taurochenodeoxycholic acid. |
| 4-hydroxycoumarin | The risk or severity of bleeding and bruising can be increased when 4-hydroxycoumarin is combined with Taurochenodeoxycholic acid. |
| Coumarin | The risk or severity of bleeding and bruising can be increased when Coumarin is combined with Taurochenodeoxycholic acid. |
| Ximelagatran | The risk or severity of bleeding and bruising can be increased when Ximelagatran is combined with Taurochenodeoxycholic acid. |
| Desmoteplase | The risk or severity of bleeding and bruising can be increased when Desmoteplase is combined with Taurochenodeoxycholic acid. |
| Ancrod | The risk or severity of bleeding and bruising can be increased when Ancrod is combined with Taurochenodeoxycholic acid. |
| Rivaroxaban | The risk or severity of bleeding and bruising can be increased when Rivaroxaban is combined with Taurochenodeoxycholic acid. |
| Sulodexide | The risk or severity of bleeding and bruising can be increased when Sulodexide is combined with Taurochenodeoxycholic acid. |
| Semuloparin | The risk or severity of bleeding and bruising can be increased when Semuloparin is combined with Taurochenodeoxycholic acid. |
| Idraparinux | The risk or severity of bleeding and bruising can be increased when Idraparinux is combined with Taurochenodeoxycholic acid. |
| Astaxanthin | The risk or severity of bleeding and bruising can be increased when Astaxanthin is combined with Taurochenodeoxycholic acid. |
| Apixaban | The risk or severity of bleeding and bruising can be increased when Apixaban is combined with Taurochenodeoxycholic acid. |
| Otamixaban | The risk or severity of bleeding and bruising can be increased when Otamixaban is combined with Taurochenodeoxycholic acid. |
| Amediplase | The risk or severity of bleeding and bruising can be increased when Amediplase is combined with Taurochenodeoxycholic acid. |
| Dabigatran etexilate | The risk or severity of bleeding and bruising can be increased when Dabigatran etexilate is combined with Taurochenodeoxycholic acid. |
| Danaparoid | The risk or severity of bleeding and bruising can be increased when Danaparoid is combined with Taurochenodeoxycholic acid. |
| Dalteparin | The risk or severity of bleeding and bruising can be increased when Dalteparin is combined with Taurochenodeoxycholic acid. |
| Tinzaparin | The risk or severity of bleeding and bruising can be increased when Tinzaparin is combined with Taurochenodeoxycholic acid. |
| (R)-warfarin | The risk or severity of bleeding and bruising can be increased when (R)-warfarin is combined with Taurochenodeoxycholic acid. |
| Ethyl biscoumacetate | The risk or severity of bleeding and bruising can be increased when Ethyl biscoumacetate is combined with Taurochenodeoxycholic acid. |
| Nadroparin | The risk or severity of bleeding and bruising can be increased when Nadroparin is combined with Taurochenodeoxycholic acid. |
| Ditazole | The risk or severity of bleeding and bruising can be increased when Ditazole is combined with Taurochenodeoxycholic acid. |
| Edoxaban | The risk or severity of bleeding and bruising can be increased when Edoxaban is combined with Taurochenodeoxycholic acid. |
| Sodium citrate | The risk or severity of bleeding and bruising can be increased when Sodium citrate is combined with Taurochenodeoxycholic acid. |
| Dextran | The risk or severity of bleeding and bruising can be increased when Dextran is combined with Taurochenodeoxycholic acid. |
| Bemiparin | The risk or severity of bleeding and bruising can be increased when Bemiparin is combined with Taurochenodeoxycholic acid. |
| Parnaparin | The risk or severity of bleeding and bruising can be increased when Parnaparin is combined with Taurochenodeoxycholic acid. |
| Desirudin | The risk or severity of bleeding and bruising can be increased when Desirudin is combined with Taurochenodeoxycholic acid. |
| Antithrombin Alfa | The risk or severity of bleeding and bruising can be increased when Antithrombin Alfa is combined with Taurochenodeoxycholic acid. |
| Protein C | The risk or severity of bleeding and bruising can be increased when Protein C is combined with Taurochenodeoxycholic acid. |
| Antithrombin III human | The risk or severity of bleeding and bruising can be increased when Antithrombin III human is combined with Taurochenodeoxycholic acid. |
| Letaxaban | The risk or severity of bleeding and bruising can be increased when Letaxaban is combined with Taurochenodeoxycholic acid. |
| Darexaban | The risk or severity of bleeding and bruising can be increased when Darexaban is combined with Taurochenodeoxycholic acid. |
| Betrixaban | The risk or severity of bleeding and bruising can be increased when Betrixaban is combined with Taurochenodeoxycholic acid. |
| Nafamostat | The risk or severity of bleeding and bruising can be increased when Nafamostat is combined with Taurochenodeoxycholic acid. |
| Monteplase | The risk or severity of bleeding and bruising can be increased when Monteplase is combined with Taurochenodeoxycholic acid. |
| Gabexate | The risk or severity of bleeding and bruising can be increased when Gabexate is combined with Taurochenodeoxycholic acid. |
| Fluindione | The risk or severity of bleeding and bruising can be increased when Fluindione is combined with Taurochenodeoxycholic acid. |
| Protein S human | The risk or severity of bleeding and bruising can be increased when Protein S human is combined with Taurochenodeoxycholic acid. |
| Brinase | The risk or severity of bleeding and bruising can be increased when Brinase is combined with Taurochenodeoxycholic acid. |
| Clorindione | The risk or severity of bleeding and bruising can be increased when Clorindione is combined with Taurochenodeoxycholic acid. |
| Diphenadione | The risk or severity of bleeding and bruising can be increased when Diphenadione is combined with Taurochenodeoxycholic acid. |
| Tioclomarol | The risk or severity of bleeding and bruising can be increased when Tioclomarol is combined with Taurochenodeoxycholic acid. |
| Melagatran | The risk or severity of bleeding and bruising can be increased when Melagatran is combined with Taurochenodeoxycholic acid. |
| Saruplase | The risk or severity of bleeding and bruising can be increased when Saruplase is combined with Taurochenodeoxycholic acid. |
| (S)-Warfarin | The risk or severity of bleeding and bruising can be increased when (S)-Warfarin is combined with Taurochenodeoxycholic acid. |
| Tocopherylquinone | The risk or severity of bleeding and bruising can be increased when Tocopherylquinone is combined with Taurochenodeoxycholic acid. |
| Dabigatran | The risk or severity of bleeding and bruising can be increased when Dabigatran is combined with Taurochenodeoxycholic acid. |
| Troxerutin | The risk or severity of bleeding and bruising can be increased when Troxerutin is combined with Taurochenodeoxycholic acid. |
| Edetic acid | The risk or severity of bleeding and bruising can be increased when Edetic acid is combined with Taurochenodeoxycholic acid. |
| Reviparin | The risk or severity of bleeding and bruising can be increased when Reviparin is combined with Taurochenodeoxycholic acid. |
| Dermatan sulfate | The risk or severity of bleeding and bruising can be increased when Dermatan sulfate is combined with Taurochenodeoxycholic acid. |
| SR-123781A | The risk or severity of bleeding and bruising can be increased when SR-123781A is combined with Taurochenodeoxycholic acid. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Taurochenodeoxycholic acid. |
| Eptifibatide | The risk or severity of adverse effects can be increased when Eptifibatide is combined with Taurochenodeoxycholic acid. |
| Ticlopidine | The risk or severity of adverse effects can be increased when Ticlopidine is combined with Taurochenodeoxycholic acid. |
| Anagrelide | The risk or severity of adverse effects can be increased when Anagrelide is combined with Taurochenodeoxycholic acid. |
| Clopidogrel | The risk or severity of adverse effects can be increased when Clopidogrel is combined with Taurochenodeoxycholic acid. |
| Tirofiban | The risk or severity of adverse effects can be increased when Tirofiban is combined with Taurochenodeoxycholic acid. |
| Pentoxifylline | The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Taurochenodeoxycholic acid. |
| Acetylsalicylic acid | The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Taurochenodeoxycholic acid. |
| Dipyridamole | The risk or severity of adverse effects can be increased when Dipyridamole is combined with Taurochenodeoxycholic acid. |
| Sulfinpyrazone | The risk or severity of adverse effects can be increased when Sulfinpyrazone is combined with Taurochenodeoxycholic acid. |
| Cilostazol | The risk or severity of adverse effects can be increased when Cilostazol is combined with Taurochenodeoxycholic acid. |
| Ridogrel | The risk or severity of adverse effects can be increased when Ridogrel is combined with Taurochenodeoxycholic acid. |
| Epoprostenol | The risk or severity of adverse effects can be increased when Epoprostenol is combined with Taurochenodeoxycholic acid. |
| Resveratrol | The risk or severity of adverse effects can be increased when Resveratrol is combined with Taurochenodeoxycholic acid. |
| Nimesulide | The risk or severity of adverse effects can be increased when Nimesulide is combined with Taurochenodeoxycholic acid. |
| Tesmilifene | The risk or severity of adverse effects can be increased when Tesmilifene is combined with Taurochenodeoxycholic acid. |
| Defibrotide | The risk or severity of adverse effects can be increased when Defibrotide is combined with Taurochenodeoxycholic acid. |
| Beraprost | The risk or severity of adverse effects can be increased when Beraprost is combined with Taurochenodeoxycholic acid. |
| Ibudilast | The risk or severity of adverse effects can be increased when Ibudilast is combined with Taurochenodeoxycholic acid. |
| Andrographolide | The risk or severity of adverse effects can be increased when Andrographolide is combined with Taurochenodeoxycholic acid. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Taurochenodeoxycholic acid. |
| Prasugrel | The risk or severity of adverse effects can be increased when Prasugrel is combined with Taurochenodeoxycholic acid. |
| Cangrelor | The risk or severity of adverse effects can be increased when Cangrelor is combined with Taurochenodeoxycholic acid. |
| Tranilast | The risk or severity of adverse effects can be increased when Tranilast is combined with Taurochenodeoxycholic acid. |
| Triflusal | The risk or severity of adverse effects can be increased when Triflusal is combined with Taurochenodeoxycholic acid. |
| Ticagrelor | The risk or severity of adverse effects can be increased when Ticagrelor is combined with Taurochenodeoxycholic acid. |
| Icosapent ethyl | The risk or severity of adverse effects can be increased when Icosapent ethyl is combined with Taurochenodeoxycholic acid. |
| Vorapaxar | The risk or severity of adverse effects can be increased when Vorapaxar is combined with Taurochenodeoxycholic acid. |